Extended-release topiramate capsules
An extended-release topiramate capsule that includes a capsule shell containing a single population of coated particles; wherein each coated particle includes a core and a coating thereon; wherein each particle core includes a homogeneous mixture comprising topiramate throughout its core; and wherein the coating includes one or more release controlling agent(s).
1. An extended-release topiramate capsule comprising:
a capsule shell comprising a single population of coated particles;
wherein each coated particle comprises a core and a coating thereon;
wherein each particle core comprises a homogeneous mixture throughout its core, the mixture comprising:
10 wt-% to 80 wt-% of topiramate, based on the total weight of an uncoated particle core;
10 wt-% to 85 wt-% of one or more filler(s), based on the total weight of an uncoated particle core; and
1 wt-% to 10 wt-% of one or more binder(s), based on the total weight of an uncoated particle core;
wherein the coating comprises:
45 wt-% to 80 wt-% of one or more release controlling agent(s), based on the total weight of the coating;
5 wt-% to 30 wt-% of one or more pore former(s), based on the total weight of the coating; and
5 wt-% to 30 wt-% of one or more plasticizer(s), based on the total weight of the coating;
wherein, when a single dose is given to a healthy human subject, an AUC 0-inf of 170 to 210 h·μg/mL within a 95% confidence interval, and a C max of 2 to 4 μg/mL within a 95% confidence interval are achieved in the subject's plasma.
2. The extended-release topiramate capsule of claim 1 which, when dosed to a healthy human subject once daily, achieves at steady-state, an AUC 0-24h , C max , and C min in the subject's plasma that are within the 80% to 125% bioequivalence criteria compared to immediate-release topiramate dosed at the same total daily dose divided twice per day.
3. The extended-release topiramate capsule of claim 1 which, when dosed to a healthy human subject once daily in the morning, achieves at steady-state, a reduction of fluctuation index of at least 15% compared to immediate-release topiramate dosed at the same total daily dose divided twice per day.
4. The extended-release topiramate capsule of claim 1 which, when dosed to a healthy human subject once daily in the morning, achieves at steady-state, a C min in the subject's plasma that is higher than the C min compared to immediate-release topiramate dosed at the same total daily dose divided twice per day.
5. The extended-release topiramate capsule of claim 1 which, when dosed once daily to a population of human patients suffering from epilepsy, achieves a reduction in incidence of at least one side effect compared to immediate-release topiramate dosed at the same total daily dose divided twice per day.
6. The extended-release topiramate capsule of claim 1 wherein the particles are coated in an amount sufficient to provide a weight gain of 2% to 30%.
7. The extended-release topiramate capsule of claim 1 which is chemically stable for at least 12 months.
8. The extended-release topiramate capsule of claim 1 wherein the capsule shell is a hydroxypropyl methylcellulose capsule.
9. The extended-release topiramate capsule of claim 1 which is free of an immediate-release component.
10. The extended-release topiramate capsule of claim 1 wherein the one or more filler(s) is selected from the group of microcrystalline cellulose, dibasic calcium phosphate, lactose, tribasic calcium phosphate, mannitol, and combinations thereof.
11. The extended-release topiramate capsule of claim 10 wherein the filler is microcrystalline cellulose.
12. The extended-release topiramate capsule of claim 1 wherein the one or more binder(s) is selected from the group of hydroxypropyl methylcellulose, methylcellulose, carboxymethylcellulose, sodium carboxymethylcellulose, hydroxypropyl cellulose, hydroxyethylcellulose, polyvinyl pyrrolidine, starch, natural gum, and combinations thereof.
13. The extended-release topiramate capsule of claim 12 wherein the binder is hydroxypropyl methylcellulose.
14. The extended-release topiramate capsule of claim 1 wherein the one or more release controlling agent(s) is selected from the group of ethylcellulose, polyvinyl acetate, polyacrylate and polymethacrylate, copolymers thereof, and combinations thereof.
15. The extended-release topiramate capsule of claim 14 wherein the release controlling agent is ethylcellulose.
16. The extended-release topiramate capsule of claim 1 wherein the one or more pore former(s) is selected from the group of hypromellose, hydroxypropyl cellulose, methylcellulose, hydroxyethylcellulose, carboxymethylcellulose, sodium carboxymethylcellulose, polyethylene glycol, guar gum, xanthan gum, sodium alginate, polyvinylpyrrolidone, crospovidone, sodium starch glycolate, croscarmellose sodium, starch, mannitol, glucose, sucrose, fructose, mannose, galactose, sorbitol, dextran, sodium chloride, potassium chloride, calcium chloride, and combinations thereof.
17. The extended-release topiramate capsule of claim 16 wherein the pore former is hydroxypropyl methylcellulose.
18. The extended-release topiramate capsule of claim 1 wherein the one or more plasticizer(s) is selected from the group of diethyl phthalate, triethyl citrate, dibutyl sebacate, polyethylene glycol, triacetin, tributyl citrate, glycerol, propylene glycol, and combinations thereof.
19. The extended-release topiramate capsule of claim 18 wherein the plasticizer is diethyl phthalate.
20. The extended-release topiramate capsule of claim 1 wherein each particle core further comprises one or more stabilizer(s) selected from the group of calcium hydroxide, calcium carbonate, sodium bicarbonate, magnesium carbonate, and combinations thereof.
21. An extended-release topiramate capsule comprising:
a capsule shell comprising a single population of coated particles;
wherein each coated particle comprises a core and a coating thereon;
wherein each particle core comprises a homogeneous mixture throughout its core,
the mixture comprising:
10 wt-% to 80 wt-% of topiramate, based on the total weight of an uncoated particle core;
10 wt-% to 85 wt-% of one or more filler(s), based on the total weight of an uncoated particle core; wherein the one or more filler(s) is selected from the group of microcrystalline cellulose, dibasic calcium phosphate, lactose, tribasic calcium phosphate, mannitol, and combinations thereof; and
1 wt-% to 10 wt-% of one or more binder(s), based on the total weight of an uncoated particle core; wherein the one or more binder(s) is selected from the group of hydroxypropyl methylcellulose, methylcellulose, carboxymethylcellulose, sodium carboxymethylcellulose, hydroxypropyl cellulose, hydroxyethylcellulose, polyvinyl pyrrolidine, starch, natural gum, and combinations thereof;
wherein the coating comprises:
45 wt-% to 80 wt-% of one or more release control agent(s), based on the total weight of the coating; wherein the one or more release controlling agent(s) is selected from the group of ethylcellulose, polyvinyl acetate, polyacrylate and polymethacrylate, copolymers thereof, and combinations thereof;
5 wt-% to 30 wt-% of one or more pore former(s), based on the total weight of the coating; wherein the one or more pore former(s) is selected from the group of hypromellose, hydroxypropyl cellulose, methylcellulose, hydroxyethylcellulose, carboxymethylcellulose, sodium carboxymethylcellulose, polyethylene glycol, guar gum, xanthan gum, sodium alginate, polyvinylpyrrolidone, crospovidone, sodium starch glycolate, croscarmellose sodium, starch, mannitol, glucose, sucrose, fructose, mannose, galactose, sorbitol, dextran, sodium chloride, potassium chloride, calcium chloride, and combinations thereof; and
5 wt-% to 30 wt-% of one or more plasticizer(s), based on the total weight of the coating; wherein the one or more plasticizer(s) is selected from the group of diethyl phthalate, triethyl citrate, dibutyl sebacate, polyethylene glycol, triacetin, tributyl citrate, glycerol, propylene glycol, and combinations thereof;
wherein, when a single dose is given to a healthy human subject, an AUC 0-inf of 170 to 210 h·μg/mL within a 95% confidence interval, and a C max of 2 to 4 μg/mL within a 95% confidence interval are achieved in the subject's plasma.
22. The extended-release topiramate capsule of claim 21 which, when dosed to a healthy human subject once daily, achieves at steady-state, an AUC 0-24h , C max , and C min in the subject's plasma that are within the 80% to 125% bioequivalence criteria compared to immediate-release topiramate dosed at the same total daily dose divided twice per day.
23. The extended-release topiramate capsule of claim 21 which, when dosed to a healthy human subject once daily in the morning, achieves at steady-state a reduction of fluctuation index of at least 15% compared to immediate-release topiramate dosed at the same total daily dose divided twice per day.
24. The extended-release topiramate capsule of claim 21 which, when dosed to a healthy human subject once daily in the morning, achieves at steady-state a C min in the subject's plasma that is higher than the C min compared to immediate-release topiramate dosed at the same total daily dose divided twice per day.
25. The extended-release topiramate capsule of claim 21 which, when dosed once daily to a population of human patients suffering from epilepsy, achieves a reduction in incidence of at least one side effect compared to immediate-release topiramate dosed at the same total daily dose divided twice per day.